Molecular docking study of britannin binding to PD-L1 and related anticancer pseudoguaianolide sesquiterpene lactones

References

• Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–452.
   PubMed Web of Science ®Google Scholar
• Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8.
   PubMed Web of Science ®Google Scholar
• Bailly C, Thuru X, Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer. 2020;2(1):zcaa002.
   PubMedGoogle Scholar
• Cheng B, Xiao Y, Xue M, et al. Recent advances in the development of PD-L1 modulators: degraders, downregulators, and covalent inhibitors. J Med Chem. 2020;63(24):15389–15398.
   PubMed Web of Science ®Google Scholar
• Zhang H, Xia Y, Yu C, et al. Discovery of novel small-molecule inhibitors of PD-1/PD-L1 interaction via structural simplification strategy. Molecules. 2021;26(11):3347.
   PubMed Web of Science ®Google Scholar
• Zyla E, Musielak B, Holak TA, et al. Structural characterization of a macrocyclic peptide modulator of the PD-1/PD-L1 immune checkpoint axis. Molecules. 2021;26(16):4848.
   PubMed Web of Science ®Google Scholar
• Liu C, Seeram NP, Ma H. Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review. Cancer Cell Int. 2021;21(1):239.
   PubMed Web of Science ®Google Scholar
• Pan C, Yang H, Lu Y, et al. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein–protein interaction or targeting PD-L1 protein degradation. Eur J Med Chem. 2021;213:113170.
   PubMed Web of Science ®Google Scholar
• Zhang YF, Zhang ZH, Li MY, et al. Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1α in cancer. Phytomedicine. 2021;81:153425.
   PubMed Web of Science ®Google Scholar
• Tong L, Li J, Li Q, et al. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics. 2020;10(13):5943–5956.
   PubMed Web of Science ®Google Scholar
• Magiera-Mularz K, Skalniak L, Zak KM, et al. Bioactive macrocyclic inhibitors of the PD-1/PD-L1 immune checkpoint. Angew Chem Int Ed Engl. 2017;56(44):13732–13735.
   PubMed Web of Science ®Google Scholar
• Zak KM, Kitel R, Przetocka S, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure. 2015;23(12):2341–2348.
   PubMed Web of Science ®Google Scholar
• Zak KM, Grudnik P, Guzik K, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016;7(21):30323–30335.
   PubMedGoogle Scholar
• Jorgensen WL, Tirado-Rives J. Molecular modeling of organic and biomolecular systems using BOSS and MCPRO. J Comput Chem. 2005;26(16):1689–1700.
   PubMed Web of Science ®Google Scholar
• Jones G, Willett P, Glen RC, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267(3):727–748.
   PubMed Web of Science ®Google Scholar
• Vergoten G, Mazur I, Lagant P, et al. The SPASIBA force field as an essential tool for studying the structure and dynamics of saccharides. Biochimie. 2003;85(1–2):65–73.
   PubMed Web of Science ®Google Scholar
• Lagant P, Nolde D, Stote R, et al. Increasing normal modes analysis accuracy: the SPASIBA spectroscopic force field introduced into the CHARMM program. J Phys Chem A. 2004;108(18):4019–4029.
   Web of Science ®Google Scholar
• Jorgensen WL, Ulmschneider JP, Tirado-Rives J. Free energies of hydration from a generalized Born model and an ALL-atom force field. J Phys Chem B. 2004;108(41):16264–16270.
   Web of Science ®Google Scholar
• Torshin IY, Namiot VA, Esipova NG, et al. Numeric analysis of reversibility of classic movement equations and constructive criteria of estimating quality of molecular dynamic simulations. J Biomol Struct Dyn. 2021;39(11):4066–4076.
   PubMed Web of Science ®Google Scholar
• Homans SW. A molecular mechanical force field for the conformational analysis of oligosaccharides: comparison of theoretical and crystal structures of Man alpha 1-3man beta 1-4GlcNAc. Biochemistry. 1990;29(39):9110–9118.
   PubMed Web of Science ®Google Scholar
• Meziane-Tani M, Lagant P, Semmoud A, et al. The SPASIBA force field for chondroitin sulfate: vibrational analysis of d-glucuronic and N-acetyl-d-galactosamine 4-sulfate sodium salts. J Phys Chem A. 2006;110(39):11359–11370.
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Tirado-Rives J. Monte Carlo versus molecular dynamics for conformational sampling. J Phys Chem. 1996;100(34):14508–14513.
   Web of Science ®Google Scholar
• Bailly C, Vergoten G. Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer. Biochem Pharmacol. 2020;178:114042.
   PubMed Web of Science ®Google Scholar
• Shi D, An X, Bai Q, et al. Computational insight into the small molecule intervening PD-L1 dimerization and the potential structure–activity relationship. Front Chem. 2019;7:764.
   PubMed Web of Science ®Google Scholar
• Guo Y, Jin Y, Wang B, et al. Molecular mechanism of small-molecule inhibitors in blocking the PD-1/PD-L1 pathway through PD-L1 dimerization. IJMS. 2021;22(9):4766.
   Google Scholar
• Guzik K, Zak KM, Grudnik P, et al. Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1. J Med Chem. 2017;60(13):5857–5867.
   PubMed Web of Science ®Google Scholar
• Lung J, Hung MS, Lin YC, et al. Virtual screening and in vitro evaluation of PD-1 dimer stabilizers for uncoupling PD-1/PD-L1 interaction from natural products. Molecules. 2020;25(22):5293.
   Web of Science ®Google Scholar
• Yang Y, Wang K, Chen H, et al. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction. Eur J Med Chem. 2021;211:113001.
   PubMed Web of Science ®Google Scholar
• Butera R, Ważyńska M, Magiera-Mularz K, et al. Design, synthesis, and biological evaluation of imidazopyridines as PD-1/PD-L1 antagonists. ACS Med Chem Lett. 2021;12(5):768–773.
   PubMed Web of Science ®Google Scholar
• Almahmoud S, Zhong HA. Molecular modeling studies on the binding mode of the PD-1/PD-L1 complex inhibitors. IJMS. 2019;20(18):4654.
   Google Scholar
• Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015;10(5):449–461.
   PubMed Web of Science ®Google Scholar
• Wang E, Sun H, Wang J, et al. End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design. Chem Rev. 2019;119(16):9478–9508.
   PubMed Web of Science ®Google Scholar
• Tuccinardi T. What is the current value of MM/PBSA and MM/GBSA methods in drug discovery? Expert Opin Drug Discov. 2021;16(11):1233–1237.
   PubMed Web of Science ®Google Scholar
• Skalniak L, Zak KM, Guzik K, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017;8(42):72167–72181.
   PubMedGoogle Scholar
• Schmidt TJ. Helenanolide-type sesquiterpene lactones – III. Rates and stereochemistry in the reaction of helenalin and related helenanolides with sulfhydryl containing biomolecules. Bioorg Med Chem. 1997;5(4):645–653.
   PubMed Web of Science ®Google Scholar
• Cotugno R, Fortunato R, Santoro A, et al. Effect of sesquiterpene lactone coronopilin on leukaemia cell population growth, cell type-specific induction of apoptosis and mitotic catastrophe. Cell Prolif. 2012;45(1):53–65.
   PubMed Web of Science ®Google Scholar
• Tian W, Chen C, Lei X, et al. CASTp 3.0: computed atlas of surface topography of proteins. Nucleic Acids Res. 2018;46(W1):W363–W367.
   PubMed Web of Science ®Google Scholar
• Siedle B, García-Piñeres AJ, Murillo R, et al. Quantitative structure–activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004;47(24):6042–6054.
   PubMed Web of Science ®Google Scholar
• Villagomez R, Hatti-Kaul R, Sterner O, et al. Effect of natural and semisynthetic pseudoguianolides on the stability of NF-κB:DNA complex studied by agarose gel electrophoresis. PLoS One. 2015;10(1):e0115819.
   PubMed Web of Science ®Google Scholar
• Widen JC, Kempema AM, Baur JW, et al. Helenalin analogues targeting NF-κB p65: thiol reactivity and cellular potency studies of varied electrophiles. ChemMedChem. 2018;13(4):303–311.
   PubMed Web of Science ®Google Scholar
• Wu G, Zhu L, Yuan X, et al. Britanin ameliorates cerebral ischemia–reperfusion injury by inducing the Nrf2 protective pathway. Antioxid Redox Signal. 2017;27(11):754–768.
   PubMed Web of Science ®Google Scholar
• Willuhn G, Pretzsch G, Wendisch D. Zwei neue pseudoguaianolide aus den blüten von arnica chamissonis less. Subsp. Genuina maguire. Tetrahedron. 1981;37(4):773–776.
   Google Scholar
• Schmidt TJ, Brun R, Willuhn G, et al. Anti-trypanosomal activity of helenalin and some structurally related sesquiterpene lactones. Planta Med. 2002;68(8):750–751.
   PubMed Web of Science ®Google Scholar
• Gertsch J, Sticher O, Schmidt T, et al. Influence of helenanolide-type sesquiterpene lactones on gene transcription profiles in Jurkat T cells and human peripheral blood cells: anti-inflammatory and cytotoxic effects. Biochem Pharmacol. 2003;66(11):2141–2153.
   PubMed Web of Science ®Google Scholar
• Sacan A, Ekins S, Kortagere S. Applications and limitations of in silico models in drug discovery. Methods Mol Biol. 2012;910:87–124.
   PubMedGoogle Scholar
• Ri MH, Ma J, Jin X. Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer. J Ethnopharmacol. 2021;281:114370.
   PubMed Web of Science ®Google Scholar